Rethiamine: frequently asked questions

Rethiamine™ is a proprietary Panacea Bio Chem research formulation: 5 mg retatrutide and 20 mg thiamine—vitamin B1—presented as a dual-layer Peptourbillon™ inside the lyophilised chamber of Lyoprester SS™, with a separate 0.5 mL P-EARLs™ reconstitution chamber. Reta-B1™ and RetaBone™ are complementary identities for the same formulation.

No. Rethiamine is a research formulation under development. Retatrutide itself is investigational, and the formulation has not been approved as a medicinal product anywhere.

It has not been established that retatrutide directly consumes or chemically depletes thiamine. The concern under investigation is indirect: powerful appetite suppression, reduced dietary intake, gastrointestinal intolerance and rapid weight reduction may leave some individuals nutritionally vulnerable.

Retatrutide produces profound metabolic and appetite effects. Panacea Bio Chem developed the Rethiamine concept in response to the emerging scientific concern that powerful appetite suppression, reduced dietary intake and gastrointestinal intolerance may leave some individuals nutritionally vulnerable. Thiamine is required for cellular energy metabolism, and humans maintain limited thiamine reserves.

Lyoprester SS™ is Panacea’s protected single-shot platform with two principal chambers: a protected lyophilised formulation chamber holding the dual-layer cake, and a separate 0.5 mL P-EARLs™ reconstitution-liquid chamber. Activation happens only immediately before use, so the components are not stored as one ready-mixed liquid.

Inside the lyophilised chamber, the retatrutide-containing peptidic liquid is introduced first and frozen as the lower layer; a separately prepared supercooled thiamine liquid is then positioned above it. The two layers are co-lyophilised in the same protected chamber while remaining spatially distinct — that layered structure is the dual-layer Peptourbillon™.

P-EARLs™ is the 0.5 mL reconstitution vehicle engineered specifically for this dual-layer formulation. Its scientific role is to reconcile or neutralise pH-, pI-, ionic-strength- and solubility-related conflicts during rapid reconstitution — an engineering objective under evaluation, supported by the analytical development programme.

The proposed 20 mg inclusion is a Panacea Bio Chem formulation-development strength. It is not presented as an established clinical requirement for individuals receiving retatrutide, and the precise pharmaceutical salt and thiamine-equivalent basis will be declared in the final analytical specification.

Reta-B1™ is the technical identity of Rethiamine — the evidence hub for retatrutide-and-thiamine research. RetaBone™ is the metabolic and body-composition research identity. All three names describe the same proprietary Panacea Bio Chem formulation, not separate products.

Rethiamine was conceived by Bogdan Dicoias within Panacea Bio Chem, and the formulation concept and platform integration are by Bogdan Dicoias and Panacea Bio Chem.